Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial.
Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K, Viswanathan P, Scalise A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJ. Docherty KF, et al. Among authors: scalise a. Circulation. 2024 Sep 29. doi: 10.1161/CIRCULATIONAHA.124.072011. Online ahead of print. Circulation. 2024. PMID: 39342512 Free article.
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Billings LK, Green JB, Koya D, Mosenzon O, Pantalone KM, Ahlers C, Lage A, Lawatscheck R, Scalise A, Bakris GL. Rossing P, et al. Among authors: scalise a. Diabetes Obes Metab. 2023 Oct;25(10):2989-2998. doi: 10.1111/dom.15197. Epub 2023 Jul 4. Diabetes Obes Metab. 2023. PMID: 37402696 Clinical Trial.
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
Rosas SE, Ruilope LM, Anker SD, Pitt B, Rossing P, Bonfanti AAC, Correa-Rotter R, González F, Munoz CFJ, Pergola P, Umpierrez GE, Scalise A, Scott C, Lawatscheck R, Joseph A, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Rosas SE, et al. Among authors: scalise a. Kidney Med. 2023 Aug 1;5(10):100704. doi: 10.1016/j.xkme.2023.100704. eCollection 2023 Oct. Kidney Med. 2023. PMID: 37745646 Free PMC article.
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone - a FIDELITY analysis.
Pitt B, Agarwal R, Anker SD, Rossing P, Ruilope L, Herzog CA, Greenberg B, Pecoits-Filho R, Lambelet M, Lawatscheck R, Scalise A, Filippatos G. Pitt B, et al. Among authors: scalise a. Eur Heart J Cardiovasc Pharmacother. 2024 Oct 8:pvae074. doi: 10.1093/ehjcvp/pvae074. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 39380152
Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
Schaefer F, Montini G, Kang HG, Walle JV, Zaritsky J, Schreuder MF, Litwin M, Scalise A, Scott H, Potts J, Iveli P, Breitenstein S, Warady BA. Schaefer F, et al. Among authors: scalise a. Trials. 2024 Mar 21;25(1):203. doi: 10.1186/s13063-024-08021-z. Trials. 2024. PMID: 38509517 Free PMC article. Clinical Trial.
GPR126 is a specifier of blood-brain barrier formation in the mouse central nervous system.
Kakogiannos N, Scalise AA, Martini E, Maderna C, Benvenuto AF, D'Antonio M, Carmignani L, Magni S, Gullotta GS, Lampugnani MG, Iannelli F, Beznoussenko GV, Mironov AA, Cerutti C, Bentley K, Philippides A, Zanardi F, Bacigaluppi M, Sigismund S, Bassani C, Farina C, Martino G, De Giovanni M, Dejana E, Iannacone M, Inverso D, Giannotta M. Kakogiannos N, et al. Among authors: scalise aa. J Clin Invest. 2024 Jun 6;134(15):e165368. doi: 10.1172/JCI165368. J Clin Invest. 2024. PMID: 39087467 Free PMC article.
153 results